Incyte Co. (NASDAQ:INCY) – Equities research analysts at Oppenheimer lifted their Q3 2018 EPS estimates for shares of Incyte in a research report issued to clients and investors on Tuesday. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of $0.18 for the quarter, up from their prior estimate of $0.13. Oppenheimer has a “Hold” rating and a $120.00 price objective on the stock. Oppenheimer also issued estimates for Incyte’s FY2018 earnings at $0.25 EPS, FY2020 earnings at $3.32 EPS and FY2022 earnings at $8.20 EPS.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. Incyte’s revenue was up 41.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.19 earnings per share.

Several other research analysts have also recently issued reports on the company. BMO Capital Markets reiterated a “buy” rating and issued a $172.00 price objective on shares of Incyte in a research report on Wednesday. Zacks Investment Research cut Incyte from a “hold” rating to a “sell” rating in a research report on Tuesday. Citigroup reiterated a “market perform” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Incyte in a research report on Tuesday. Royal Bank of Canada upgraded Incyte from a “sector perform” rating to an “outperform” rating and set a $136.00 price objective for the company in a research report on Tuesday. Finally, Deutsche Bank began coverage on Incyte in a research report on Tuesday, December 12th. They issued a “hold” rating and a $106.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Incyte currently has an average rating of “Buy” and a consensus price target of $143.11.

Incyte (NASDAQ INCY) traded down $2.59 during trading hours on Thursday, reaching $98.39. The company’s stock had a trading volume of 860,948 shares, compared to its average volume of 1,470,000. The stock has a market capitalization of $20,760.00, a PE ratio of -122.99 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte has a 1 year low of $92.91 and a 1 year high of $153.15.

Several institutional investors and hedge funds have recently bought and sold shares of INCY. Tower Research Capital LLC TRC boosted its stake in shares of Incyte by 13.8% during the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 108 shares during the last quarter. Seven Eight Capital LP acquired a new stake in shares of Incyte during the second quarter valued at $129,000. Sun Life Financial INC boosted its stake in shares of Incyte by 9,069.2% during the second quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,179 shares during the last quarter. Private Advisor Group LLC acquired a new stake in shares of Incyte during the third quarter valued at $203,000. Finally, Symphony Asset Management LLC boosted its stake in shares of Incyte by 20.1% during the second quarter. Symphony Asset Management LLC now owns 1,867 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 312 shares during the last quarter. 90.74% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Paul A. Friedman sold 28,507 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $105.24, for a total transaction of $3,000,076.68. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vijay K. Iyengar sold 5,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total value of $486,300.00. The disclosure for this sale can be found here. Insiders sold 38,118 shares of company stock worth $3,968,133 in the last three months. 17.70% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Q3 2018 EPS Estimates for Incyte Co. Boosted by Analyst (INCY)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/q3-2018-eps-estimates-for-incyte-co-boosted-by-analyst-incy.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.